Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis – a systematic review and meta-analysis of randomized controlled trials

References

• Albaaj F, Hutchison AJ. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. Expert Opin Pharmacother 2005;6:319-28
   PubMed Web of Science ®Google Scholar
• Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-33
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
   PubMed Web of Science ®Google Scholar
• Toida T. A 9-month extension study of a crossover study to evaluate the efficacy of lanthanum carbonate vs. calcium carbonate in hemodialysis patients. Therapeut Res 2012;33:929-33
   Google Scholar
• National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201
   Google Scholar
• Tonelli M, Pannu N, Manns B. Drug therapy: oral phosphate binders in patients with kidney failure. N Engl J Med 2010;362:1312-24
   PubMed Web of Science ®Google Scholar
• Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009;20:388-96
   PubMed Web of Science ®Google Scholar
• Hutchison AJ. Oral phosphate binders. Kidney Int 2009;75:906-14
   PubMed Web of Science ®Google Scholar
• Spasovski G, Massy Z, Vanholder R. Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management. Semin Dial 2009;22:357-62
   PubMed Web of Science ®Google Scholar
• Hutchison AJ. Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant 2004;19(Suppl 1):i19-24
   PubMedGoogle Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83
   PubMed Web of Science ®Google Scholar
• London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-40
   PubMed Web of Science ®Google Scholar
• Oka Y, Miyazaki M, Takatsu S, et al. Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. Ther Apher Dial 2007;11:107-13
   PubMed Web of Science ®Google Scholar
• Finn WF. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006;65:191-202
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Maes B, Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006;102:c61-71
   PubMed Web of Science ®Google Scholar
• D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol (TM)) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003;63:S73-8
   Web of Science ®Google Scholar
• Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008
   Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58
   PubMed Web of Science ®Google Scholar
• Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003;42:96-107
   PubMed Web of Science ®Google Scholar
• Finn WF, Joy MS, Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004;62:193-201
   PubMed Web of Science ®Google Scholar
• Al-Baaj F, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant 2005;20:775-82
   PubMed Web of Science ®Google Scholar
• Chiang SS, Chen JB, Yang WC. Lanthanum carbonate (Fosrenol (R)) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005;63:461-70
   PubMed Web of Science ®Google Scholar
• Shigematsu T, Sakai T, Iwasaki M, et al. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial 2008;12:55-61
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang YX, Yu XQ, et al. Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China. BMC Nephrol 2013;14:29
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Gill M, Copley JB, et al. Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients. BMC Nephrol 2013;14:40
   PubMed Web of Science ®Google Scholar
• Damment SJ, Pennick M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008;47:553-63
   PubMed Web of Science ®Google Scholar
• Floege J, Raggi P, Block GA, et al. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2010;25:1916-23
   PubMed Web of Science ®Google Scholar
• Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-42
   PubMed Web of Science ®Google Scholar
• Goto S, Komaba H, Moriwaki K, et al. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol 2011;6:1375-84
   PubMed Web of Science ®Google Scholar
• Brennan A, Akehurst R, Davis S, et al. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. Value Health 2007;10:32-41
   PubMed Web of Science ®Google Scholar
• Park H, Rascati KL, Keith MS, et al. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value Health 2011;14:1002-9
   PubMed Web of Science ®Google Scholar
• Vegter S, Tolley K, Keith MS, et al. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective. Clin Ther 2012;34:1531-43
   PubMed Web of Science ®Google Scholar